{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-020701","form_type":"8-K","ticker":"MRMD","cik":"0001522767","company_name":"MARIMED INC.","filed_at":"2021-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.379286+00:00","generated_at":"2026-06-29T08:54:50.762608+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MariMed Q2 revenue $32.6M (+239% YoY); raises FY2021 guidance to $118M revenue, $32M EBITDA","bullets":["Revenue $32.6M, up 239% YoY and 32% QoQ; net income $7.6M vs loss $1.1M in Q2 2020.","EBITDA $12.3M (+440% YoY); Adjusted EBITDA $13.9M (43% margin).","Raises FY2021 guidance: revenue to $118M (from $100M), EBITDA to $32M (from $30M); first-time Adj. EBITDA guide of $42M.","Positive operating cash flow $10.8M; working capital $20.9M, up $7.2M from Q1.","Growth driven by wholesale in MA, retail in MA/IL, and branded product licensing in six states."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-020701","json":"https://secwatch.observer/filing/0001493152-21-020701.json","markdown":"https://secwatch.observer/filing/0001493152-21-020701.md","text":"https://secwatch.observer/filing/0001493152-21-020701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1522767/000149315221020701/0001493152-21-020701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1522767/000149315221020701/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:54:50.762608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}